抗体药物偶联物在复发难治性弥漫大B细胞淋巴瘤中的应用进展

Progress in application of antibody-drug conjugates in the treatment of relapsed refractory DLBCL

弥漫大B细胞淋巴瘤(DLBCL)患者在接受R-CHOP标准方案治疗后,仍有一部分患者症状复发或难治,预后很差。抗体药物偶联物对肿瘤发挥高效杀伤作用的同时,不损伤正常组织及细胞,成为不可或缺的治疗策略。多种药物已通过严格的临床试验并表现出良好的有效性及可控范围内的安全性,临床试验的开展也为抗体药物偶联物的下一步发展指明了方向。

After the standard treatment of R-CHOP regimen, some patients with diffuse large B-cell lymphoma still have relapse or refractory disease, and the prognosis of them is poor.Antibody-drug conjugates can effectively kill tumors while avoiding damage to normal tissues and cells, becoming an indispensable treatment strategy at the moment.Many drugs have passed rigorous clinical trials and have shown good efficacy and controlled safety, and the development of clinical trials also indicates the direction for the future development of antibody-drug conjugates.